Prognostic value of loss of heterozygosity at BRCA2 in human breast carcinoma
1997

BRCA2 Loss and Breast Cancer Prognosis

Sample size: 102 publication Evidence: low

Author Information

Author(s): I Bieche, C Nogubs, S Rivoilan, A Khodja, A Latill, R Lidereau

Primary Institution: Centre Rene Huguenin

Hypothesis

Is loss of heterozygosity at BRCA2 a significant prognostic factor in sporadic breast cancer?

Conclusion

Loss of heterozygosity at BRCA2 does not appear to be a major prognostic marker in sporadic breast cancer.

Supporting Evidence

  • LOH at BRCA2 was found in 42.4% of informative tumor DNAs.
  • No link was found between BRCA2 status and macroscopic tumor size or lymph node status.
  • Oestrogen and progesterone receptor negativity were associated with a higher percentage of LOH at BRCA2.

Takeaway

The study looked at breast cancer patients to see if a specific genetic change (BRCA2 loss) could predict how well they would do. It found that this change doesn't really help in predicting outcomes.

Methodology

The study examined 102 primary breast tumors for loss of heterozygosity at BRCA2 and analyzed patient outcomes over a median follow-up of 9 years.

Limitations

The study focused only on sporadic breast cancer and may not apply to hereditary cases.

Participant Demographics

Participants were 102 women with primary unilateral invasive breast carcinoma, aged 34-86 years.

Statistical Information

P-Value

P = 0.34 for metastasis-free survival, P = 0.29 for overall survival

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication